AACR 2024 | Are pre-leukemic mutations necessary for disease pathogenesis following disease initiation?
Ravindra Majeti, MD, PhD, Stanford University, Stanford, CA, describes advances that have been made in cancer genomics to establish the differential role of genomic mutations at each stage of leukemia, from disease initiation to disease establishment. It is necessary to explore the role of genomic mutations that are required for disease initiation and determine whether they are also necessary for disease pathogenesis once leukemia has been established. Dr Majeti notes that looking at the order of mutations that are initiated in genes regulating the epigenome is one particular method to establish the role of various mutations. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
